Improved Diagnosis and Management of Kawasaki Disease: Key Insights from AHA’s New Scientific Statement

Advances in cardiac imaging and risk categorization have improved the diagnosis and treatment of Kawasaki Disease, according to a new statement from the American Heart Association in the journal Circulation.

Key Points:

• Kawasaki Disease primarily affects children under five. It inflames blood vessels and is the leading cause of acquired heart disease in children in developed countries.

• The cause of Kawasaki Disease is unknown, but it is suspected to be infectious. Diagnosis relies on symptoms like prolonged fever, rash, and reddened eyes. Without treatment, up to 25% of children may develop coronary artery issues.

• Health professionals evaluate coronary artery abnormalities using Z-scores, which compare the diameter of affected arteries to those of healthy children. A Z-score above 2.5 signals an increased risk for aneurysms. Consistent Z-score equations are necessary for accurate risk classification.

• Identifying high-risk children early is crucial for effective treatment. A new risk scoring system considers factors such as age under six months, Asian descent, high Z-scores, and elevated C-reactive protein levels.

• Regular echocardiograms, especially for those with higher Z-scores, are recommended to monitor any coronary artery abnormalities.

• Intravenous immunoglobulin (IVIG) is the standard treatment. Adjusting doses based on a patient’s weight can reduce complications.

• Recent studies suggest that low to medium doses of aspirin may be as effective as high doses during the acute phase of Kawasaki Disease.

• Additional treatments like corticosteroids or infliximab may benefit children resistant to IVIG.

• For children with significant aneurysms, blood thinners like aspirin and anticoagulants may prevent blood clots. New direct oral anticoagulants might offer safer alternatives, though more research is needed.

• The COVID-19 pandemic led to an increase in a related condition, Multisystem Inflammatory Syndrome in Children (MIS-C), which shares symptoms with Kawasaki Disease. New research helps differentiate between the two.

• Medical centers treating Kawasaki Disease should have a dedicated heart team to manage cardiac events.

• A formal transition program for adolescents and adults with a history of Kawasaki Disease is necessary for ongoing care, especially for those with giant aneurysms.

• Pregnant women with a history of Kawasaki Disease require specialized care to manage heart risks.

This statement emphasizes the importance of early detection and tailored treatments in managing Kawasaki Disease to improve outcomes for affected patients.